Medtronic OmniaSecure™ defibrillation lead is the first lead of its kind to receive FDA approval for conduction system pacing

Medtronic (NYSE: MDT) received FDA approval (March 23, 2026) for an expanded indication for the OmniaSecure defibrillation lead to enable placement in the left bundle branch (LBB) area for conduction system pacing (CSP).

Rhea-AI Summary

Medtronic (NYSE: MDT) received FDA approval (March 23, 2026) for an expanded indication for the OmniaSecure defibrillation lead to enable placement in the left bundle branch (LBB) area for conduction system pacing (CSP).

The lumenless, 4.7 French lead is approved for adults and adolescent patients ages 12+, showed 100% defibrillation success at implant and a 2.1% OmniaSecure-related major complication rate at three months in the LEADR LBBAP trial, and commercially launched in the U.S. in January 2026.

Positive

• FDA approval for LBB area conduction system pacing (March 23, 2026)
• Defibrillation success at implant: 100% in LEADR LBBAP
• Three-month major complication rate related to OmniaSecure: 2.1%
• Smallest diameter defibrillation lead on market: 4.7 French
• Approved for adolescents ages 12 and up
• U.S. commercial launch of OmniaSecure in January 2026

Negative

• Longer-term outcomes pending: extended LBB area and LOT-CRT results to be presented at HRS 2026
• Not approved for pediatric patients under age 12

Argus Mar 23 session

+1.17% close to close Open Argus

Details

News Market Reaction – MDT

On Mar 23, the day this news came out, MDT closed 1.17% above the previous close.

Data tracked by StockTitan Argus for the Mar 23 session.

Market Context

This announcement adds a notable FDA approval to Medtronic’s cardiovascular portfolio, making OmniaS...

Analysis

This announcement adds a notable FDA approval to Medtronic’s cardiovascular portfolio, making OmniaSecure the first defibrillation lead cleared for conduction system pacing in the left bundle branch area, with 100% implant defibrillation success and a 2.1% major complication rate. In context of multiple recent FDA approvals across other franchises, investors may focus on clinical uptake, real-world performance beyond the LEADR trial, and how this innovation contributes to broader cardiac rhythm management growth.

Key Figures

Defibrillation success at implant: 100% Major complication rate: 2.1% Lead diameter: 4.7 French +5 more

Defibrillation success at implant

100%

LEADR LBBAP trial OmniaSecure performance at implant

Major complication rate

2.1%

OmniaSecure-related major complications at three months in LBB area use

Lead diameter

4.7 French

Smallest diameter defibrillation lead on the market

Lead diameter (mm)

1.66 mm

Physical size of OmniaSecure defibrillation lead

Minimum patient age

12 years

Approved for adults and adolescent pediatric patients ages 12 and up

Patients with 3830 lead

More than one million

Global implants of SelectSecure Model 3830 pacing lead

Employees

95,000+

Global Medtronic workforce across more than 150 countries

Health conditions treated

70

Number of health conditions addressed by Medtronic technologies

Previous Fda approval Reports

5 past events · Latest: 2026-02-02

Same Type 5 events

1. 2026-02-02

   Diabetes FDA clearance

   24h Move

   -0.2%

   Medicare access and new FDA clearances expanding MiniMed 780G insulin options.

2. 2025-09-19

   Bladder device approval

   24h Move

   -0.5%

   FDA approval of Altaviva ITNM device for urge urinary incontinence treatment.

3. 2025-09-02

   780G system expansion

   24h Move

   +0.6%

   FDA milestones integrating 780G with Instinct sensor and type 2 diabetes use.

4. 2025-04-18

   Sensor FDA approval

   24h Move

   -1.0%

   FDA approval of Simplera Sync sensor for use with MiniMed 780G system.

5. 2025-02-24

   DBS system approval

   24h Move

   +0.3%

   FDA approval of BrainSense Adaptive DBS and Electrode Identifier for Parkinson’s.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

conduction system pacing, left bundle branch, cardiac resynchronization therapy, implantable cardioverter-defibrillator, +4 more

8 terms

conduction system pacing medical

"the lead can be used for conduction system pacing (CSP), which closely mimics"

A heart-rhythm treatment where a pacemaker lead is placed to directly stimulate the heart’s natural electrical wiring so each beat follows the heart’s own pathway, producing a more natural and coordinated contraction—think of fixing a traffic signal at its source instead of directing cars from the side. It matters to investors because better outcomes and fewer complications can change demand for specific devices, shift hospital purchasing and reimbursement patterns, and influence which manufacturers and technologies gain market share.

left bundle branch medical

"Now approved for placement in the left bundle branch (LBB) area, the lead can"

A left bundle branch is one of the heart’s main electrical “wires” that carries signals into the left lower chamber so it contracts in time with the rest of the heart; think of it as part of the wiring that keeps the heartbeat coordinated. Investors should care because damage or blockage here shows up on medical tests, can drive demand for treatments, devices or monitoring, and can affect clinical trial outcomes, regulatory reviews, and healthcare costs.

cardiac resynchronization therapy medical

"patients in need of cardiac resynchronization may benefit from left bundle"

A treatment that uses a small implanted device, similar to a pacemaker, to send timed electrical pulses that make the heart’s lower chambers beat in sync so it can pump blood more effectively. Investors watch it because the therapy drives demand for medical devices, hospital procedures and related services, and because its clinical success and insurance coverage can influence sales, regulatory risk and long-term growth for companies in the cardiac care market.

implantable cardioverter-defibrillator medical

"lead connects to an implantable cardioverter-defibrillator (ICD) or cardiac"

An implantable cardioverter-defibrillator (ICD) is a small electronic device placed under the skin near the chest that monitors the heartbeat and delivers a corrective electric shock or gentle pacing when it detects dangerous fast or irregular heart rhythms. Investors care because ICDs represent a durable medical-device market with upfront device sales, follow-up care and replacement procedures, and outcomes, safety records and regulatory approvals can materially affect a manufacturer’s revenue and valuation—think of it as a built-in safety device for the heart.

ventricular tachyarrhythmias medical

"to treat potentially life-threatening ventricular tachyarrhythmias, ventricular"

A rapid, abnormal heartbeat originating in the heart’s lower chambers that can disrupt normal pumping and sometimes lead to fainting or sudden cardiac arrest; think of it like an engine misfiring that prevents a car from running smoothly. Investors care because these arrhythmias drive demand for treatments, devices, hospital care and drug approvals, influence clinical study outcomes and regulatory risk, and can materially affect a company’s revenue and liability exposure.

ventricular fibrillation medical

"ventricular tachyarrhythmias, ventricular fibrillation (VT/VF), and"

A life-threatening heart condition in which the heart’s electrical signals become chaotic and the lower chambers quiver instead of pumping blood effectively, like a car engine misfiring so it can’t move the vehicle. It matters to investors because it drives demand for emergency care, medical devices, drugs and diagnostics, affects clinical trial outcomes and regulatory decisions, and can influence healthcare costs, insurer liabilities and the valuation of companies tied to cardiac treatment.

lumenless technical

"with its lumenless construction (no hollow channel on the inside), which"

Lumenless describes a medical or technical device that has no hollow channel running through it — a solid shaft rather than a tube. For investors, this matters because a lumenless design can change how a product is made, used and regulated: it may be stronger, thinner or less prone to blockages but cannot carry fluids or wires, which affects manufacturing costs, performance claims, market fit and potential safety or approval considerations. Think of it like comparing a solid metal rod to a straw.

extravascular medical

"the Medtronic extravascular Aurora EV-ICD™ system offers protection as the"

Extravascular means located or occurring outside the body's blood vessels, describing tissues, fluids, or medical devices that are not inside veins or arteries. For investors, extravascular matters because whether a drug, implant, or bleed is inside or outside blood vessels can change how a treatment is delivered, its safety and effectiveness, trial results and regulatory scrutiny—like whether water is inside or outside a pipe, which alters how you fix a leak and the cost implications.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Built for high reliability, world's only lumenless defibrillation lead approved for placement in the left bundle branch area

GALWAY, Ireland, March 23, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for an expanded indication for the OmniaSecure™ defibrillation lead. Now approved for placement in the left bundle branch (LBB) area, the lead can be used for conduction system pacing (CSP), which closely mimics the heart's natural physiology. Additionally, patients in need of cardiac resynchronization may benefit from left bundle branch optimized cardiac resynchronization therapy (LOT-CRT), a novel therapy that combines CSP with left-ventricular pacing to further improve patient outcomes.

The OmniaSecure defibrillation lead connects to an implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) to treat potentially life-threatening ventricular tachyarrhythmias, ventricular fibrillation (VT/VF), and bradyarrhythmias. In addition to being the first defibrillation lead approved for placement in the LBB area, the OmniaSecure lead is the smallest diameter defibrillation lead on the market (4.7 French, or 1.66 mm) and the only one approved for adults and adolescent pediatric patients ages 12 and up.

Engineered based on the reliable Medtronic SelectSecure™ Model 3830 pacing lead − the first pacing lead to receive FDA approval for CSP in 2022 − the OmniaSecure defibrillation lead is built for high reliability and durability with its lumenless construction (no hollow channel on the inside), which enables the lead to be delivered via catheter for precise placement in the right ventricle, in addition to the LBB area. Conduction system pacing works by tapping into the heart's natural electrical system, providing patients needed therapy while avoiding cardiomyopathy or other complications sometimes associated with traditional pacing methods.¹

"Conduction system pacing is a rapidly growing therapy for patients who need a pacemaker. Now, patients who require a defibrillator and pacing have an option that can safely deliver life-saving defibrillation therapy and activate the heart's natural electrical system to enable a more synchronous, physiologic pattern," said Trevor Cook, vice president and general manager of the Defibrillation Solutions business, which is part of the Cardiac Rhythm Management operating unit at Medtronic. "This approval underscores the versatility of the OmniaSecure defibrillation lead and supports its use across a variety of implant approaches to best serve a broad range of patients."

ICDs and CRT-Ds are the gold standard for preventing sudden cardiac arrest. For patients who require chronic pacing and defibrillation therapy, the OmniaSecure lead can offer treatment for dangerously fast arrhythmias while delivering conduction system pacing through the LBB area, when connected to a transvenous ICD or CRT-D, such as the Medtronic Cobalt™ and Crome™ family of devices. Patients indicated for CRT may benefit when OmniaSecure is paired with a left ventricular coronary sinus lead (i.e., biventricular or LOT-CRT configurations). For patients who do not require chronic pacing, the Medtronic extravascular Aurora EV-ICD™ system offers protection as the only ICD with a defibrillation lead positioned outside the vascular space that also provides anti-tachycardia pacing (ATP) in a single device.

FDA approval for the OmniaSecure defibrillation lead was supported by data from the global LEADR LBBAP trial (Lead Evaluation for Defibrillation and Reliability in Left Bundle Branch Area Pacing), which demonstrated the lead's safety and effectiveness. Late-breaking data from the study presented at Heart Rhythm 2025, and later published in Heart Rhythm, showed that the lead delivered high defibrillation success at implant (100%) and a low OmniaSecure-related major complication rate at three months (2.1%) when placed in the LBB area for physiologic pacing.² Longer-term LBB area and LOT-CRT results from the study will be presented at HRS 2026.

"The robust body of clinical evidence from the LEADR LBBAP study supports the OmniaSecure defibrillation lead as a safe and effective way to activate physiologic pacing through the left bundle branch area or in applications like LOT-CRT, while also demonstrating reliable defibrillation success," said Pugazhendhi Vijayaraman, M.D., cardiac electrophysiologist at Geisinger Wyoming Valley Medical Center in Wilkes-Barre, Pa., and principal investigator of the LEADR LBBAP study.

The approval expands the comprehensive Medtronic portfolio of lumenless leads and accessories approved by FDA that enable conduction system pacing. This includes the SelectSecure Model 3830 pacing lead, now implanted in more than one million patients globally, as well as the recently cleared C320LBB delivery catheter and the 5944RL rotatable connector. Together, these CSP solutions deliver stability and long-term performance that further enhance procedural precision and versatility.

Following FDA approval for placement in traditional locations in the right ventricle, the OmniaSecure defibrillation lead launched commercially in the U.S. in January 2026.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. 

Contacts:
Joey Lomicky
Public Relations
+1-763-526-2494

Ingrid Goldberg
Investor Relations
+1-763-505-2696

1 Padala SK and Ellenbogen KA. Card Electrophysiol Clin. 2021;13(4):755-84.

2 Vijayaraman P, et al. Heart Rhythm. Published online October 17, 2025.

View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-omniasecure-defibrillation-lead-is-the-first-lead-of-its-kind-to-receive-fda-approval-for-conduction-system-pacing-302720215.html

SOURCE Medtronic plc

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What FDA approval did Medtronic (MDT) announce for the OmniaSecure lead on March 23, 2026?

The OmniaSecure lead received FDA approval to be placed in the left bundle branch area for conduction system pacing. According to the company, this expands use to CSP and supports LOT-CRT when paired with a left-ventricular lead.

What clinical results supported Medtronic's OmniaSecure FDA approval (MDT)?

The LEADR LBBAP trial showed 100% defibrillation success at implant and a 2.1% OmniaSecure-related major complication rate at three months. According to the company, these outcomes demonstrated safety and effectiveness for LBB area placement.

Which patients are eligible for the OmniaSecure defibrillation lead (MDT) after the approval?

The lead is approved for adults and adolescent pediatric patients ages 12 and up for ICD or CRT-D therapy. According to the company, it supports CSP and LOT-CRT configurations with a left-ventricular coronary sinus lead.

What are the device features of Medtronic's OmniaSecure lead (MDT) relevant to clinicians?

OmniaSecure is lumenless, delivered via catheter, and measures 4.7 French (1.66 mm), the smallest defibrillation lead on the market. According to the company, the design enables precise LBB and right-ventricle placement.

When did Medtronic (MDT) begin commercial sales of the OmniaSecure defibrillation lead in the U.S.?

Medtronic launched OmniaSecure commercially in the U.S. in January 2026. According to the company, the product was previously approved for traditional right-ventricle locations before the LBB area indication.